Cetuximab News and Research

RSS
Cetuximab is an investigational IgG1 monoclonal antibody designed to target and block the Epidermal Growth Factor Receptor (EGFR), which is expressed on the surface of certain cancer cells in multiple tumor types. Cetuximab is designed to bind to EGFR and prevent natural ligands called growth factors from binding to the receptor and inducing phosphorylation, i.e., activation of signaling to the tumor. The most common drug-related adverse events reported in clinical trials of cetuximab have been an acne-like rash and asthenia. Severe allergic reactions may occur in a small percentage of patients.
Recommendations on new cancer drug review process fall short in several ways: CCAC

Recommendations on new cancer drug review process fall short in several ways: CCAC

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

Transgenomic secures exclusive license from Montefiore for cancer predictive markers

Transgenomic secures exclusive license from Montefiore for cancer predictive markers

Boehringer Ingelheim's new afatinib-cetuximab phase Ib data in NSCLC presented at ASCO 2011

Boehringer Ingelheim's new afatinib-cetuximab phase Ib data in NSCLC presented at ASCO 2011

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Biothera begins dosing in Imprime PGG and cetuximab combination Phase III trial for colorectal cancer

Biothera begins dosing in Imprime PGG and cetuximab combination Phase III trial for colorectal cancer

Pfizer seeks U.S. FDA, Japanese MHLW approval for crizotinib NDA to treat ALK-positive advanced NSCLC

Pfizer seeks U.S. FDA, Japanese MHLW approval for crizotinib NDA to treat ALK-positive advanced NSCLC

Researchers help explain why smart drugs are not effective in some cancer patients

Researchers help explain why smart drugs are not effective in some cancer patients

ArQule reports net loss of $1,466,000 for first quarter 2011

ArQule reports net loss of $1,466,000 for first quarter 2011

Brain-derived protein in colorectal cancer

Brain-derived protein in colorectal cancer

Biothera's Phase II clinical trials in lung cancer attain stage 1 endpoint

Biothera's Phase II clinical trials in lung cancer attain stage 1 endpoint

Oncothyreon's ONT-10, PX-866 preclinical data presented at AACR meeting

Oncothyreon's ONT-10, PX-866 preclinical data presented at AACR meeting

Merck submits Erbitux indication extension to EMA for NSCLC treatment

Merck submits Erbitux indication extension to EMA for NSCLC treatment

USPTO grants patent to Symphogen's Sym004 to treat solid tumors

USPTO grants patent to Symphogen's Sym004 to treat solid tumors

U-M scientists identify potential target to treat aggressive prostate cancer

U-M scientists identify potential target to treat aggressive prostate cancer

AVEO receives USAN, WHO generic name approval for ficlatuzumab

AVEO receives USAN, WHO generic name approval for ficlatuzumab

ArQule's ARQ 197 Phase 1 clinical trial results in colorectal cancer presented at ASCO 2011

ArQule's ARQ 197 Phase 1 clinical trial results in colorectal cancer presented at ASCO 2011

New long-term survival data from OPUS, CRYSTAL studies demonstrate strong tumor shrinkage of Erbitux

New long-term survival data from OPUS, CRYSTAL studies demonstrate strong tumor shrinkage of Erbitux

Pfizer initiates rolling submission of crizotinib NDA for ALK-positive advanced NSCLC

Pfizer initiates rolling submission of crizotinib NDA for ALK-positive advanced NSCLC

Choosing between EGFR therapeutic options in metastatic colorectal cancer

Choosing between EGFR therapeutic options in metastatic colorectal cancer